๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS ยท Real-Time Price ยท USD
2.500
-0.140 (-5.30%)
At close: Nov 19, 2026, 4:00 PM EST
2.510
+0.010 (0.40%)
After-hours: Nov 19, 2026, 4:10 PM EST

Intensity Therapeutics Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Study Result

    INT230-6, an intratumoral therapy combining SHAO, cisplatin, and vinblastine, showed high tumor retention, favorable safety, and promising efficacy in metastatic solid tumors, especially when โ‰ฅ40% of tumor burden was injected. Median overall survival reached 12โ€“19 months, with evidence of immune activation and abscopal effects.

  • AGM 2025

    Stockholders approved both a reverse stock split and an adjournment proposal, with the Board retaining discretion over the timing and ratio of the split. Final voting results will be disclosed in a Form 8-K. Forward-looking statements were noted as subject to risk factors.

  • AGM 2025

    The meeting confirmed a quorum, elected Dr. Mark A. Goldberg as Director through 2028, and ratified EisnerAmper LLP as auditors for 2025. No questions were raised by stockholders, and management highlighted standard forward-looking statement risks.

Fiscal Year 2024